Empowering Nucleic Acid Delivery for Breakthrough Therapies
Your nucleic acid therapy breakthrough begins the minute you choose Avanti Research, where you have access to unmatched resources and technical expertise. Our research-use-only (RUO) nucleic acid delivery solutions are not just products – they are the tools for your success. Whether you are developing gene therapies, mRNA vaccines and cancer immunotherapies, or RNA interference and other genome-editing technologies, our extensive portfolio of lipid-based carriers and innovative transfection reagents delivers unmatched versatility for developing the next generation of transformational therapeutics.
A Tailored Approach to Your Research Need
The challenge is always different, the needs are always different, but with Avanti Research, you have access to a full spectrum of top-quality materials in a variety of pack sizes to allow you to fulfill your needs at the scale that matches your project plan. Are you taking your first step towards a better delivery system, or fine-tuning your formulation? Whatever the stage of your project, our catalogue is your opportunity to start experimenting, without wasting valuable time or funds.
Advanced Transfection Agents for Viral Vector Production
Transfection efficiency is a primary determinant of viral vector titers and robust vector yields, and Avanti Research offers much more than lipid carriers, offering a broad range of transfection agents to augment viral vector production efficiency by efficiently transfecting producer cells.
Comprehensive Support for Every Step of the Way
In addition to the right materials, the recipe for nucleic acid delivery success also includes the right technical support. The team at Avanti Research is available to help with both. Our extensive portfolio of lipids and transfection agents is a direct outcome of over 45 years of lipid chemistry and formulation science expertise to meet your needs whether you produce lipid nanoparticles (LNPs) for nucleic acid delivery, viral vectors, and more. Our technical experts can advise you on materials selection, scale-up, optimization and best-practice techniques.
Resources:
Cullis PR, Hope MJ. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther. 2017 Jul 5;25(7):1467-1475. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813/
Jayaraman et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.
Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470698/
Wan C, Allen TM, Cullis PR. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv Transl Res. 2014 Feb;4(1):74-83. https://link.springer.com/article/10.1007/s13346-013-0161-z